ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research

The ALS Therapy Development Institute (ALS TDI) announced that a collection of cells derived from ALS patient-derived iPSC lines will now be made widely available to researchers around the world.